UK medical and life sciences research and development under spotlight:
This article was originally published in Clinica
Executive Summary
The strategy and management of the UK's medical and life sciences research are the subject of the House of Commons' Science and Technology Committee's first oral hearing on the work of the research council institutes. The meeting, which is open to the public and takes place in Westminster on June 28 (full details at www.parliament.uk/s&tcom), will hear evidence from Professor Julia Goodfellow, chief executive of the Biotechnology and Biological Sciences Research Council, and Professor Colin Blakemore, chief executive of the Medical Research Council. The STC last week published its report on research council support for knowledge transfer, which highlights the importance of fully engaging industry and better observing the needs of small and medium-sized enterprises (SMEs).
You may also be interested in...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.